After testing ResMed's new sleep apnoea therapy platform, patients rate the S9 Series as significantly better than their current device in comfort of breathing, dryness of nose and mouth, rainout, and noise. In terms of overall preference, 78% preferred the S9 Series, over their current device.
"For the first time with our new ClimateControl™ system, air is delivered quietly and comfortably at the precise temperature and humidity that the sleeping patient, provider, and physician have set. S9 Series provides a significant, patient-perceptible difference in comfort; a true leap-forward for sleep apnoea therapy," said Michael Farrell, SVP of the Global Sleep Business Unit at ResMed.
Studies conducted by researchers at Harvard Medical School show that a lack of sleep negatively affects perception and judgment. In the workplace sleep deprivation can result in reduced efficiency and productivity, errors, and accidents. Studies from the Clinical Sciences Research Institute at the University of Warwick suggest that between 6-8 hours of sleep is the optimal range.
"We are extremely pleased to see patient tests confirm that the S9 Series increases patient's compliance and quality of life, making the device a true revolution in positive airway pressure therapy," added Frank Klein, VP, European Sleep Business Unit at ResMed.
About the study
The ResMed S9 Compliance Study was conducted as a clinical study of 50 patients at the ResMed Sleep Research Centre in Sydney, Australia. The three month study comprised three stages: a retrospective study where the patients used their own device for 28 days, followed by 28 days testing S9 in a prospective study, and finally returning to the patient's own device for 28 more days in a prospective study.
The purpose of the study was to assess whether compliance is improved by ResMed's new S9 Series, which features reduced noise, an improved humidifi
Copyright©2010 PR Newswire.
All rights reserved